Key result
The AT1R A1166C polymorphism was not significantly associated with the risk of type 2 diabetes mellitus or diabetic nephropathy.
Why the study?
Does the AT1R A1166C polymorphism increase the risk of type 2 diabetes mellitus and diabetic nephropathy in an Iranian population?
Case-Control (n=233)
No
Does the AT1R A1166C polymorphism increase the risk of type 2 diabetes mellitus and diabetic nephropathy in an Iranian population?
Absolute Event Rate: 26.7% vs 26.5%
p-value: p=0.98
No support for AT1R A1166C in T2DM or nephropathy risk assessment; leaves open other genetic contributions in Iranians.
No takes yet. Share an insight, caveat, or question.
Moradi et al. (2015) conducted a case-control in Type 2 diabetes mellitus and diabetic nephropathy (n=233). AT1R A1166C polymorphism vs. Healthy controls was evaluated on Frequency of AT1R AC+CC genotype in diabetic patients compared to healthy controls (p=0.98). The AT1R A1166C polymorphism was not significantly associated with the risk of type 2 diabetes mellitus or diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: